Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study

Detalhes bibliográficos
Autor(a) principal: Pereira, M
Data de Publicação: 2014
Outros Autores: Araújo, C, Dias, P, Lunet, N, Subirana, I, Marrugat, J, Capewell, S, Bennett, K, Azevedo, A
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10216/114849
Resumo: Aim: To assess the proportion of patients receiving pharmacological therapy for secondary prevention after an acute coronary syndrome (ACS) in Portugal and to identify age and sex inequalities. Design: Retrospective cohort study. Methods: We studied 747 episodes of ST-segment elevation myocardial infarction (STEMI) and 1364 of non-ST-segment elevation ACS (NSTE-ACS), within a sample of ACS cases consecutively discharged from 10 Portuguese hospitals, in 2008–2009. We estimated adjusted odds ratios (OR) for the association of age and sex with the use of each pharmacological treatment. Results: In STEMI and NSTE-ACS patients, the proportion of patients discharged with aspirin was 96 and 88%, clopidogrel 91 and 78%, aspirin+clopidogrel 88 and 71%, beta-blockers 80 and 76%, angiotensin-converting enzyme (ACE) inhibitors/ARB 82 and 80%, statins 93 and 90%, 3-drug (aspirin/clopidogrel+beta-blocker+statin) 76 and 69%, and 5-drug treatment (aspirin+clopidogrel+beta-blocker+ACE inhibitor/ARB+statin) 61 and 48%, respectively. Among STEMI patients, those aged ≥80 years were substantially less often discharged with clopidogrel (OR 0.22, 95% confidence interval, CI, 0.08–0.56), aspirin+clopidogrel (OR 0.34, 95% CI 0.15–0.76), beta-blockers (OR 0.39, 95% CI 0.18–0.82), 3-drug (OR 0.41, 95% CI 0.21–0.83), and 5-drug treatments (OR 0.44, 95% CI 0.23–0.83) than those <60 years; women were less likely to be discharged with aspirin+clopidogrel (OR 0.52, 95% CI 0.29–0.91). Among NSTE-ACS patients, those aged ≥80 years were much less likely to be discharged with beta-blockers (OR 0.58, 95% CI 0.36–0.93), statins (OR 0.35, 95% CI 0.19–0.64), and 3-drug treatment (OR 0.47, 95% CI 0.30–0.75); sex had no significant effect on treatment prescription. Conclusions: The vast majority of younger patients were discharged on evidence-based secondary preventive medications, but only half received the 5-drug combination. Recommended therapies were substantially underprescribed in older patients.
id RCAP_1625d774c1613c03b51f36a80942f7a4
oai_identifier_str oai:repositorio-aberto.up.pt:10216/114849
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP studyAcute coronary syndromePharmacological therapyAim: To assess the proportion of patients receiving pharmacological therapy for secondary prevention after an acute coronary syndrome (ACS) in Portugal and to identify age and sex inequalities. Design: Retrospective cohort study. Methods: We studied 747 episodes of ST-segment elevation myocardial infarction (STEMI) and 1364 of non-ST-segment elevation ACS (NSTE-ACS), within a sample of ACS cases consecutively discharged from 10 Portuguese hospitals, in 2008–2009. We estimated adjusted odds ratios (OR) for the association of age and sex with the use of each pharmacological treatment. Results: In STEMI and NSTE-ACS patients, the proportion of patients discharged with aspirin was 96 and 88%, clopidogrel 91 and 78%, aspirin+clopidogrel 88 and 71%, beta-blockers 80 and 76%, angiotensin-converting enzyme (ACE) inhibitors/ARB 82 and 80%, statins 93 and 90%, 3-drug (aspirin/clopidogrel+beta-blocker+statin) 76 and 69%, and 5-drug treatment (aspirin+clopidogrel+beta-blocker+ACE inhibitor/ARB+statin) 61 and 48%, respectively. Among STEMI patients, those aged ≥80 years were substantially less often discharged with clopidogrel (OR 0.22, 95% confidence interval, CI, 0.08–0.56), aspirin+clopidogrel (OR 0.34, 95% CI 0.15–0.76), beta-blockers (OR 0.39, 95% CI 0.18–0.82), 3-drug (OR 0.41, 95% CI 0.21–0.83), and 5-drug treatments (OR 0.44, 95% CI 0.23–0.83) than those <60 years; women were less likely to be discharged with aspirin+clopidogrel (OR 0.52, 95% CI 0.29–0.91). Among NSTE-ACS patients, those aged ≥80 years were much less likely to be discharged with beta-blockers (OR 0.58, 95% CI 0.36–0.93), statins (OR 0.35, 95% CI 0.19–0.64), and 3-drug treatment (OR 0.47, 95% CI 0.30–0.75); sex had no significant effect on treatment prescription. Conclusions: The vast majority of younger patients were discharged on evidence-based secondary preventive medications, but only half received the 5-drug combination. Recommended therapies were substantially underprescribed in older patients.20142014-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10216/114849eng2047-487310.1177/2047487313494580Pereira, MAraújo, CDias, PLunet, NSubirana, IMarrugat, JCapewell, SBennett, KAzevedo, Ainfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-29T14:47:23Zoai:repositorio-aberto.up.pt:10216/114849Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:08:29.562875Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study
title Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study
spellingShingle Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study
Pereira, M
Acute coronary syndrome
Pharmacological therapy
title_short Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study
title_full Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study
title_fullStr Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study
title_full_unstemmed Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study
title_sort Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: the EURHOBOP study
author Pereira, M
author_facet Pereira, M
Araújo, C
Dias, P
Lunet, N
Subirana, I
Marrugat, J
Capewell, S
Bennett, K
Azevedo, A
author_role author
author2 Araújo, C
Dias, P
Lunet, N
Subirana, I
Marrugat, J
Capewell, S
Bennett, K
Azevedo, A
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Pereira, M
Araújo, C
Dias, P
Lunet, N
Subirana, I
Marrugat, J
Capewell, S
Bennett, K
Azevedo, A
dc.subject.por.fl_str_mv Acute coronary syndrome
Pharmacological therapy
topic Acute coronary syndrome
Pharmacological therapy
description Aim: To assess the proportion of patients receiving pharmacological therapy for secondary prevention after an acute coronary syndrome (ACS) in Portugal and to identify age and sex inequalities. Design: Retrospective cohort study. Methods: We studied 747 episodes of ST-segment elevation myocardial infarction (STEMI) and 1364 of non-ST-segment elevation ACS (NSTE-ACS), within a sample of ACS cases consecutively discharged from 10 Portuguese hospitals, in 2008–2009. We estimated adjusted odds ratios (OR) for the association of age and sex with the use of each pharmacological treatment. Results: In STEMI and NSTE-ACS patients, the proportion of patients discharged with aspirin was 96 and 88%, clopidogrel 91 and 78%, aspirin+clopidogrel 88 and 71%, beta-blockers 80 and 76%, angiotensin-converting enzyme (ACE) inhibitors/ARB 82 and 80%, statins 93 and 90%, 3-drug (aspirin/clopidogrel+beta-blocker+statin) 76 and 69%, and 5-drug treatment (aspirin+clopidogrel+beta-blocker+ACE inhibitor/ARB+statin) 61 and 48%, respectively. Among STEMI patients, those aged ≥80 years were substantially less often discharged with clopidogrel (OR 0.22, 95% confidence interval, CI, 0.08–0.56), aspirin+clopidogrel (OR 0.34, 95% CI 0.15–0.76), beta-blockers (OR 0.39, 95% CI 0.18–0.82), 3-drug (OR 0.41, 95% CI 0.21–0.83), and 5-drug treatments (OR 0.44, 95% CI 0.23–0.83) than those <60 years; women were less likely to be discharged with aspirin+clopidogrel (OR 0.52, 95% CI 0.29–0.91). Among NSTE-ACS patients, those aged ≥80 years were much less likely to be discharged with beta-blockers (OR 0.58, 95% CI 0.36–0.93), statins (OR 0.35, 95% CI 0.19–0.64), and 3-drug treatment (OR 0.47, 95% CI 0.30–0.75); sex had no significant effect on treatment prescription. Conclusions: The vast majority of younger patients were discharged on evidence-based secondary preventive medications, but only half received the 5-drug combination. Recommended therapies were substantially underprescribed in older patients.
publishDate 2014
dc.date.none.fl_str_mv 2014
2014-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10216/114849
url http://hdl.handle.net/10216/114849
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2047-4873
10.1177/2047487313494580
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136010090577921